James V. Alvarez

Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa — South Africa

Biochemistry, Genetics and Molecular Biology · Life Sciences

23h-index2.8kcitations162works0.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer, Hypoxia, and Metabolism(41), Lung Cancer Treatments and Mutations(37), Epigenetics and DNA Methylation(21), Cancer Cells and Metastasis(20), Estrogen and related hormone effects(17)

Publications161 total

Abstract B019: SOX2 induction and ΔNp63-high subpopulations mark adaptive responses to EGFR inhibition in lung adenocarcinoma
Cancer Research·2025
Recurrent Breast Cancer Cells Depend on <i>De novo</i> Pyrimidine Biosynthesis to Suppress Ferroptosis
2025
Data from Targeting the Dependence on PIK3C3-mTORC1 Signaling in Dormancy-Prone Breast Cancer Cells Blunts Metastasis Initiation
2025Open Access
Supplementary Data from Targeting the Dependence on PIK3C3-mTORC1 Signaling in Dormancy-Prone Breast Cancer Cells Blunts Metastasis Initiation
2025Open Access
Figure S1-S10 from Targeting the Dependence on PIK3C3-mTORC1 Signaling in Dormancy-Prone Breast Cancer Cells Blunts Metastasis Initiation
2025Open Access
Supplementary Tables from Targeting the Dependence on PIK3C3-mTORC1 Signaling in Dormancy-Prone Breast Cancer Cells Blunts Metastasis Initiation
2025Open Access
Figure 1 from APOBEC3 Activity Promotes the Survival and Evolution of Drug-Tolerant Persister Cells during EGFR Inhibitor Resistance in Lung Cancer
2025Open Access
Table S1 from APOBEC3 Activity Promotes the Survival and Evolution of Drug-Tolerant Persister Cells during EGFR Inhibitor Resistance in Lung Cancer
2025Open Access
Data from APOBEC3 Activity Promotes the Survival and Evolution of Drug-Tolerant Persister Cells during EGFR Inhibitor Resistance in Lung Cancer
2025Open Access
Figure 5 from APOBEC3 Activity Promotes the Survival and Evolution of Drug-Tolerant Persister Cells during EGFR Inhibitor Resistance in Lung Cancer
2025Open Access
Supplementary File 1 from APOBEC3 Activity Promotes the Survival and Evolution of Drug-Tolerant Persister Cells during EGFR Inhibitor Resistance in Lung Cancer
2025Open Access
Figure S1 from APOBEC3 Activity Promotes the Survival and Evolution of Drug-Tolerant Persister Cells during EGFR Inhibitor Resistance in Lung Cancer
2025Open Access
Figure S7 from APOBEC3 Activity Promotes the Survival and Evolution of Drug-Tolerant Persister Cells during EGFR Inhibitor Resistance in Lung Cancer
2025Open Access
Table S2 from APOBEC3 Activity Promotes the Survival and Evolution of Drug-Tolerant Persister Cells during EGFR Inhibitor Resistance in Lung Cancer
2025Open Access
Figure 2 from APOBEC3 Activity Promotes the Survival and Evolution of Drug-Tolerant Persister Cells during EGFR Inhibitor Resistance in Lung Cancer
2025Open Access
Figure S5 from APOBEC3 Activity Promotes the Survival and Evolution of Drug-Tolerant Persister Cells during EGFR Inhibitor Resistance in Lung Cancer
2025Open Access
Figure S2 from APOBEC3 Activity Promotes the Survival and Evolution of Drug-Tolerant Persister Cells during EGFR Inhibitor Resistance in Lung Cancer
2025Open Access
Figure 6 from APOBEC3 Activity Promotes the Survival and Evolution of Drug-Tolerant Persister Cells during EGFR Inhibitor Resistance in Lung Cancer
2025Open Access
Figure S6 from APOBEC3 Activity Promotes the Survival and Evolution of Drug-Tolerant Persister Cells during EGFR Inhibitor Resistance in Lung Cancer
2025Open Access
Figure 3 from APOBEC3 Activity Promotes the Survival and Evolution of Drug-Tolerant Persister Cells during EGFR Inhibitor Resistance in Lung Cancer
2025Open Access
page 1 of 9Next →

Frequent Co-authors

Ryan Lupo(11), David A. Frank(9), Brock J. McKinney(9), Nina Marie G. Garcia(8), Ashley V. DiMarco(8), Lewis A. Chodosh(8), Nathaniel W. Mabe(8), Douglas B. Fox(7), Rachel Newcomb(7), Jeffrey S. Damrauer(7), Andrea Walens(6), Kouros Owzar(6), Chao‐Chieh Lin(5), Jen‐Tsan Chi(5), Matthew D. Hirschey(4), Benjamin Kroger(4), Tien-Chi Pan(4), Jeremy Force(4), Jichun Xie(4), Heidi Greulich(3)